方舟生物醫藥 ABIO 深 滬
等待開盤 08-13 09:30:00 美东时间
2.40
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.40
- 總市值 3480.26万
- 52周最高 34.524
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 -0.636
- 委 比 0.00%
- 總股本 1450.11万
- 歷史最高 3821.124
- 量 比 0
- 振 幅 0.00%
- 歷史最低 -0.636
- 每 手 1
- 風險率 6.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Assembly Biosciences announced interim Phase 1a clinical trial results for ABI-6250, an oral HDV entry inhibitor. Data showed a mean half-life of four days, supporting daily dosing, and dose-dependent increases in total serum bile acids, indicating NTCP target engagement. Safety profiles were manageable, with Grade 1-2 ALT elevations observed, all self-limiting. The company plans further pharmacological assessment alongside Phase 2 preparations. ...
08-06 20:05
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
Assembly Biosciences announces the start of Phase 1b trials for ABI-1179, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor, targeting recurrent genital herpes. The study evaluates safety and antiviral activity with weekly oral dosing over 29 days. Concurrent Phase 1b studies for ABI-1179 and ABI-5366 are ongoing, with interim data expected by fall 2025. Both candidates showed favorable PK profiles in Phase 1a, and ABI-1179 demo...
06-30 12:00
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
Assembly Biosciences announced positive Phase 1b results for ABI-4334, a next-generation capsid assembly modulator for chronic hepatitis B (HBV). The study showed potent antiviral activity and favorable safety profiles across both 150 mg and 400 mg cohorts, with mean HBV DNA reductions of 2.9 and 3.2 logs IU/mL, respectively. Pharmacokinetic data supported once-daily dosing, with exposure levels exceeding targets for viral replication inhibition ...
06-25 12:00
国投证券-生物医药行业新药周观点：脓毒症治疗迎来新突破，远大医药STC3141中国2期成功-250518
（转自：研报虎） 本周新药行情回顾： 2025年5月12日-2025年5月16日，新药板块涨幅前5企业：君圣泰(19.78%)、德琪医药(18.34%)...
05-18 17:56
Panacea Biotec Announces Departure of Independent Director
Panacea Biotec Limited ( ($IN:PANACEABIO) ) has issued an update. Panacea Biote...
03-30 14:43
药明康德(603259.SH)：拟认购私募基金份额
格隆汇12月19日丨药明康德(603259.SH)公布，全资子企业WuXiPharmaTechHealthcareFundIL.P.（简称“WuXiFundI...
2024-12-19 18:01
ARCA biopharma approves 1-for-12 reverse stock split
Pharmaceutical company ARCA biopharma (NASDAQ:ABIO) said on Friday its board has approved a reverse stock split of its shares at a ratio of 1-for-12. ARCA’s (ABIO) stock is expected to begin trading o...
2024-08-24 05:37
Why ARCA Biopharma Shares Are Trading Higher Today
ARCA Biopharma shares are trading higher by 8.1% Monday morning. The company announced a special dividend of $1.59 per share.
2024-08-19 22:28
Estée Lauder, Palo Alto Networks And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stock...
2024-08-19 15:47
ARCA Biopharma shares are trading higher after the company announced a special dividend of $1.59 per share.
ARCA Biopharma shares are trading higher after the company announced a special ...
2024-08-17 04:37
